An estimated 18% of older (≥ 65) adults suffer from mild cognitive impairment (MCI). More than half will progress to dementia within 5 years. Primary prevention may be by recognition of the true burden of anticholinergic drugs on cognition and avoidance wherever possible. This project aimed to systematically review the literature to update a widely used scale that assesses anti-cholinergic burden (ACB scale) and establish the impact of drugs with anticholinergic properties on cognitive function in patients over the age of 18 without a diagnosis of dementia.
Maidment, I., Chan, W-Y., Bua, N., Myint, P., Campbell, N., Boustani, M., Kwok, C. S., & Fox, C. (2013). An updated systematic review of the impact of medications with anticholinergic activity on cognitive function and mortality. Alzheimer's and Dementia, 9(4), P774. https://doi.org/10.1016/j.jalz.2013.05.1578